Matrix Pharma Private Limited (Acquirer) does not presently carry out any business activity either in India or outside India.
Kotak Strategic Situations India Fund II (Investor 1) is an alternative investment fund registered with the Securities and Exchange Board of India (SEBI) under the SEBI (Alternative Investment Funds) Regulations, 2012. It is engaged in the business of investing in companies with a sector agnostic approach. It invests in portfolio vehicles with the objective of obtaining primarily long-term capital appreciation and returns in the nature of interest, dividend, capital gains or share of profits on its investments through a combination of appropriate instruments.
Kotak Alternate Asset Managers Limited (Investor 2) acts as an investment manager, engaged in the business of managing and advising funds across the following asset classes namely: (a) Special Situations; (b) Real Estate; (c) Infrastructure; (d) Private Equity; and (e) Private Credit. It curates investment products for investors and manages these to invest in unique and interesting investment opportunities relevant to the Indian markets and financing requirements of businesses. [Investor 1 and Investor 2, together referred to as “Investors”)
Tianish Laboratories Private Limited (Target) has been incorporated to carry out the business of manufacture and sale of active pharmaceutical ingredients in India.
The Acquirer proposes to purchase 100% of the equity shares of the Target. Prior to the Acquirer’s acquisition of the Target, the Investors propose to subscribe to certain optionally convertible debentures of the Acquirer, the proceeds of which investment will be utilised by the Acquirer towards its acquisition of the Target (Proposed Combination).
Detailed order of the Commission will follow.
Picture Source :
